Skip to main content
Clinical Trials/PACTR202201655513401
PACTR202201655513401
Not yet recruiting
未知

Efficacy and safety of four-weeks versus twelve-weeks loading doses spacing of intravitreal Aflibercept for treatment of macular edema associated with Central Retinal Vein Occlusion

Egypt health insurance0 sites60 target enrollmentJanuary 6, 2022
ConditionsEye Diseases

Overview

Phase
未知
Intervention
Not specified
Conditions
Eye Diseases
Sponsor
Egypt health insurance
Enrollment
60
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 6, 2022
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Egypt health insurance

Eligibility Criteria

Inclusion Criteria

  • Any participant to be included in the study should have:
  • normal or controlled blood pressure.
  • normal Hba1c or controlled (maximum 6\.5%).
  • normal or controlled lipogram.
  • Patients aged \=18 years with center\-involved macular edema due to CRVO (CMT \=250 µm on OCT).
  • Best corrected visual acuity (BCVA) of 20/40 to 20/320 (73 to 24 letters)

Exclusion Criteria

  • Exclusion criteria comprised the following:
  • pregnancy or lactation.
  • previous vitreoretinal or filtration surgery.
  • iris neovascularization.
  • any systemic or ocular disorder in the study eye that may confound the interpretation of the study results.
  • previous treatment with any anti\-VEGF agents.
  • systemic anti\-angiogenic medications.
  • intraocular corticosteroids

Outcomes

Primary Outcomes

Not specified

Similar Trials